207 related articles for article (PubMed ID: 34715591)
1. Dynamics of AQP4 upon exposure to seropositive patient serum before and after Rituximab therapy in Neuromyelitis Optica: A cell-based study.
Saha S; Mukherjee S; Guha G; Mukhopadhyay D
J Neuroimmunol; 2021 Dec; 361():577752. PubMed ID: 34715591
[TBL] [Abstract][Full Text] [Related]
2. Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1/M23 isoform content, or supramolecular assembly.
Rossi A; Ratelade J; Papadopoulos MC; Bennett JL; Verkman AS
Glia; 2012 Dec; 60(12):2027-39. PubMed ID: 22987455
[TBL] [Abstract][Full Text] [Related]
3. Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1/M23 isoforms and orthogonal arrays.
Crane JM; Lam C; Rossi A; Gupta T; Bennett JL; Verkman AS
J Biol Chem; 2011 May; 286(18):16516-24. PubMed ID: 21454592
[TBL] [Abstract][Full Text] [Related]
4. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies.
Nicchia GP; Mastrototaro M; Rossi A; Pisani F; Tortorella C; Ruggieri M; Lia A; Trojano M; Frigeri A; Svelto M
Glia; 2009 Oct; 57(13):1363-73. PubMed ID: 19229993
[TBL] [Abstract][Full Text] [Related]
5. Optic neuritis in neuromyelitis optica.
Levin MH; Bennett JL; Verkman AS
Prog Retin Eye Res; 2013 Sep; 36():159-71. PubMed ID: 23545439
[TBL] [Abstract][Full Text] [Related]
6. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
Jarius S; Aboul-Enein F; Waters P; Kuenz B; Hauser A; Berger T; Lang W; Reindl M; Vincent A; Kristoferitsch W
Brain; 2008 Nov; 131(Pt 11):3072-80. PubMed ID: 18945724
[TBL] [Abstract][Full Text] [Related]
7. Aquaporin-4 Mz isoform: brain expression, supramolecular assembly and neuromyelitis optica antibody binding.
Rossi A; Crane JM; Verkman AS
Glia; 2011 Jul; 59(7):1056-63. PubMed ID: 21491501
[TBL] [Abstract][Full Text] [Related]
8. Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays.
Iorio R; Fryer JP; Hinson SR; Fallier-Becker P; Wolburg H; Pittock SJ; Lennon VA
J Autoimmun; 2013 Feb; 40():21-7. PubMed ID: 22906356
[TBL] [Abstract][Full Text] [Related]
9. Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity.
Pisani F; Sparaneo A; Tortorella C; Ruggieri M; Trojano M; Mola MG; Nicchia GP; Frigeri A; Svelto M
PLoS One; 2013; 8(11):e79185. PubMed ID: 24260168
[TBL] [Abstract][Full Text] [Related]
10. Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays.
Phuan PW; Ratelade J; Rossi A; Tradtrantip L; Verkman AS
J Biol Chem; 2012 Apr; 287(17):13829-39. PubMed ID: 22393049
[TBL] [Abstract][Full Text] [Related]
11. Aquaporin-4: orthogonal array assembly, CNS functions, and role in neuromyelitis optica.
Verkman AS; Ratelade J; Rossi A; Zhang H; Tradtrantip L
Acta Pharmacol Sin; 2011 Jun; 32(6):702-10. PubMed ID: 21552296
[TBL] [Abstract][Full Text] [Related]
12. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.
Ahn SH; Kim SM; Sung JJ
Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297
[TBL] [Abstract][Full Text] [Related]
13. Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid.
Marignier R; Ruiz A; Cavagna S; Nicole A; Watrin C; Touret M; Parrot S; Malleret G; Peyron C; Benetollo C; Auvergnon N; Vukusic S; Giraudon P
J Neuroinflammation; 2016 May; 13(1):111. PubMed ID: 27193196
[TBL] [Abstract][Full Text] [Related]
14. Neuromyelitis Optica Immunoglobulin G present in sera from neuromyelitis optica patients affects aquaporin-4 expression and water permeability of the astrocyte plasma membrane.
Melamud L; Fernández JM; Rivarola V; Di Giusto G; Ford P; Villa A; Capurro C
J Neurosci Res; 2012 Jun; 90(6):1240-8. PubMed ID: 22354518
[TBL] [Abstract][Full Text] [Related]
15. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.
Tradtrantip L; Zhang H; Saadoun S; Phuan PW; Lam C; Papadopoulos MC; Bennett JL; Verkman AS
Ann Neurol; 2012 Mar; 71(3):314-22. PubMed ID: 22271321
[TBL] [Abstract][Full Text] [Related]
16. [Neuromyelitis optica and anti-aquaporin 4 antibody--an overview].
Misu T; Fujihara K; Itoyama Y
Brain Nerve; 2008 May; 60(5):527-37. PubMed ID: 18516975
[TBL] [Abstract][Full Text] [Related]
17. AQP4ex is crucial for the anchoring of AQP4 at the astrocyte end-feet and for neuromyelitis optica antibody binding.
Palazzo C; Buccoliero C; Mola MG; Abbrescia P; Nicchia GP; Trojano M; Frigeri A
Acta Neuropathol Commun; 2019 Apr; 7(1):51. PubMed ID: 30935410
[TBL] [Abstract][Full Text] [Related]
18. Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO.
Verkman AS; Phuan PW; Asavapanumas N; Tradtrantip L
Brain Pathol; 2013 Nov; 23(6):684-95. PubMed ID: 24118484
[TBL] [Abstract][Full Text] [Related]
19. Role of the H-bond between L53 and T56 for Aquaporin-4 epitope in Neuromyelitis Optica.
Pisani F; Simone L; Gargano CD; De Bellis M; Cibelli A; Mola MG; Catacchio G; Frigeri A; Svelto M; Nicchia GP
Biochim Biophys Acta Biomembr; 2017 Mar; 1859(3):368-376. PubMed ID: 28027883
[TBL] [Abstract][Full Text] [Related]
20. Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders.
Duan T; Tradtrantip L; Phuan PW; Bennett JL; Verkman AS
Neuropharmacology; 2020 Jan; 162():107827. PubMed ID: 31654702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]